How long will tigecycline's patent be extended?

When does tigecycline's patent expire?

Tigecycline's basic product patent expired in 2018. The drug's market exclusivity in the US extended through December 2024 due to pediatric exclusivity and other protections. The main compound patent covering tigecycline expired earlier than that, but several secondary patents listed in the FDA Orange Book still affect generic entry.

How long will tigecycline's patent be extended?

No further extensions are currently planned or expected. The remaining listed patents and exclusivity periods have already reached their projected end dates. Any new claims or new indications would be needed to request a new extension, but no such applications are publicly tracked at this time.

What patents remain on tigecycline?

The FDA Orange Book still lists several method-of-use and formulation patents that are due to expire between 2025 and 2028 in some cases. These secondary claims often cover specific treatment regimes or formulation improvements, but they do not extend the compound itself.

Why are companies challenging tigecycline patents?

Multiple generic manufacturers filed Paragraph IV certifications against the listed patents, challenging their validity or non-infringement. These challenges led to litigation that was eventually settled, settling dates for generic launches.

When can generics enter the market?

Generics entered the US market in January 2025 after the December 2024 exclusivity expired. Several companies have already launched or are ready to launch under settlement agreements.

What happens if a new indication gets approved?

A new indication would not automatically extend the existing patent term. Any new indication could earn three years of new data exclusivity if supported by new clinical data, but it would not revive the expired compound patent.

How does tigecycline compare with other antibiotics?

Tigecycline belongs to the glycylcycline class and provides broad-spectrum coverage against MRSA and ESBL-producing bacteria. It differs from older tetracyclines in its evasion of efflux pumps and resistance mechanisms.